Becotatug Vedotin Plus PD-1 Monoclonal Antibody and Radiotherapy for Unresectable Locally Recurrent Nasopharyngeal Carcinoma

NCT07555860 · clinicaltrials.gov ↗

PHASE2

Phase

NOT_YET_RECRUITING

Status

28

Enrollment

OTHER

Sponsor class

Conditions

Nasopharyngeal Carcinoma

Interventions

DRUG: Becotatug Vedotin
DRUG: Toripalimab
DRUG: Camrelizumab
DRUG: Intensity-Modulated Radiotherapy

Sponsor

Sun Yat-sen University